Signity Pharmaceuticals Private Limited, a active private limited company, was established on 13 September 2010 in Nagpur, Maharashtra, India. Engaging in drug formulation & development within the trade sector, it holds CIN: U74900MH2010PTC207591. Registered under ROC Roc Mumbai. it is unlisted. It has an authorized capital of ₹2.00 Cr and a paid-up capital of ₹6.49 M.
It upholds a compliant status. Employing 45 professional, Its leadership includes Bhupendra Bhaskar Marliwar (Director), Saiye Bhupendra Marliwar (Additional Director), Bhraman Bhaskar Marliwar (Additional Director). Past directors included Samir Deodatta Sawwalakhe, Vishalkumar Sunderlal Mulani, Shridhar Diwakar Dhavle. It holds ₹4.00 Cr open charges and no settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at Plot No.10, Ground Floor , Dnyanyog Apartment, Deo Nagar, Khamla Road, Nagpur, Maharashtra, 440015.
U74900MH2010PTC207591
207591
13 September 2010
₹2.00 Cr
₹6.49 M
Roc Mumbai
Unlisted
Active
Explore comprehensive insights into Signity Pharmaceuticals Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Bhupendra Bhaskar Marliwar | Director | 13 Sep 2010 | Current |
| Saiye Bhupendra Marliwar | Additional Director | 19 Jul 2025 | Current |
| Bhraman Bhaskar Marliwar | Additional Director | 19 Jul 2025 | Current |
| Bhushan Bhaskar Marliwar | Additional Director | 22 Aug 2025 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 08 Jan 2015 | Past |
| Pramod Abcsdd | Additional Director | 30 Sep 2019 | Past |
| Pramod Abcsdd | Director | - | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Signity Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 16.43% increase. The company also saw a slight improvement in profitability, with a 2.11% increase in profit. The company's net worth Soared by an impressive increase of 20.86%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Signity Pharmaceuticals had a public holding of 57.65%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹40,000,000.00
₹0
| Date | Lender | Amount | Status |
|---|---|---|---|
| 11 Sep 2025 | Others | ₹4.00 Cr | Open |
Explore comprehensive loan charge details -
Signity Pharmaceuticals has a workforce of 45 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Signity Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Signity Pharmaceuticals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
A charge with Others amounted to Rs. 4.00 Cr with Charge ID 101158725 was registered on 11 Sep 2025. was recorded as a recent event.
A charge with Others of Rs. 4.00 Cr registered on 11 Sep 2025 with Charge ID 101158725 was modified on 11 Sep 2025. was recorded as a recent event.
Progress on Bhushan Bhaskar Marliwar was appointed as a Additional Director was appointed as a Additional Director on 22 Aug 2025 & has been associated with this company since 3 months 9 days . was documented.
Saiye Bhupendra Marliwar was appointed as a Additional Director was appointed as a Additional Director on 19 Jul 2025 & has been associated with this company since 4 months 13 days . was recorded as a recent event.
The activity Bhraman Bhaskar Marliwar was appointed as a Additional Director was appointed as a Additional Director on 19 Jul 2025 & has been associated with this company since 4 months 13 days . was completed.
Progress on Signity Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was documented.
The CIN of Signity Pharmaceuticals Private Limited is U74900MH2010PTC207591.
Signity Pharmaceuticals Private Limited is headquartered at Plot No.10, Ground Floor , Dnyanyog Apartment, Deo Nagar, Khamla Road, Nagpur, Maharashtra, 440015.
Signity Pharmaceuticals Private Limited was incorporated on 13 September 2010.
The current directors of Signity Pharmaceuticals Private Limited are
The primary industry of Signity Pharmaceuticals Private Limited is Trade.
Signity Pharmaceuticals Private Limited is unlisted.
The authorized capital of Signity Pharmaceuticals Private Limited is ₹2.00 Cr, and the paid-up capital is ₹6.49 M.
The compliance status of Signity Pharmaceuticals Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX